# PDE2A

## Overview
PDE2A is a gene that encodes the enzyme phosphodiesterase 2A, which is a member of the phosphodiesterase family of proteins. This enzyme is primarily involved in the hydrolysis of cyclic nucleotides, specifically cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), playing a critical role in cellular signaling pathways. Phosphodiesterase 2A is characterized by its complex structure, which includes regulatory GAF domains and a catalytic domain essential for its enzymatic activity (Martinez2002The; Iffland2005Structural). The protein is expressed in various tissues, with significant roles in the brain, heart, and endothelial cells, where it influences processes such as vascular homeostasis and mitochondrial function (Sadhu1999Differential; Lobo2020Phosphodiesterase). Through its interactions with other proteins and involvement in critical signaling pathways, PDE2A is implicated in several physiological and pathological processes, making it a potential target for therapeutic interventions (Lobo2020Phosphodiesterase; Monterisi2017PDE2A2).

## Structure
The PDE2A protein is characterized by a complex molecular structure that includes both regulatory and catalytic domains. The primary structure of PDE2A is encoded by the PDE2A gene, and the protein can exist in multiple splice variant isoforms, contributing to its functional diversity (Hamza2009Determination). The secondary structure of PDE2A includes alpha-helices and beta-sheets, with the catalytic domain composed of fifteen α-helices and six 3_10 helices (Iffland2005Structural).

The tertiary structure of PDE2A features a catalytic domain with a conserved metal-binding site, crucial for its enzymatic activity. This domain is organized into three subdomains, with the active site primarily located within the third subdomain, bounded by several helices and loop regions (Iffland2005Structural). The regulatory segment of PDE2A includes two GAF domains, GAF A and GAF B, which play distinct roles in dimerization and cGMP binding, respectively (Martinez2002The).

PDE2A forms homodimers, representing its quaternary structure, with dimerization facilitated by the GAF A domains (Martinez2002The). The protein undergoes conformational changes upon cGMP binding, which are significant for its regulatory function (Pandit2009Mechanism). These structural features are essential for the enzyme's role in hydrolyzing cyclic nucleotides like cAMP and cGMP.

## Function
Phosphodiesterase 2A (PDE2A) is an enzyme that plays a crucial role in the regulation of cyclic nucleotide signaling by hydrolyzing cAMP and cGMP, which are key intracellular signaling molecules. PDE2A is involved in modulating the crosstalk between cAMP and cGMP pathways, particularly in response to elevated cGMP levels, which enhances cAMP hydrolysis (Pandit2009Mechanism; Sadhu1999Differential). This enzyme is expressed in various tissues, with significant activity in the brain, heart, and endothelial cells, where it influences vascular homeostasis and endothelial cell function (Sadhu1999Differential).

In endothelial cells, PDE2A is predominantly found in venous and capillary endothelial cells, suggesting a role in regulating fluid and inflammatory cell transit through the endothelial barrier (Sadhu1999Differential). The enzyme's activity is regulated by its N-terminal GAF domains, which undergo conformational changes upon cGMP binding, allowing substrate access to the catalytic domain (Pandit2009Mechanism).

PDE2A also plays a role in mitochondrial function, particularly through its isoform PDE2A2, which regulates mitophagy by modulating cAMP levels and influencing the recruitment of Parkin to mitochondria (Lobo2020Phosphodiesterase). This regulation is crucial for maintaining mitochondrial quality control and cellular homeostasis (Lobo2020Phosphodiesterase).

## Clinical Significance
Mutations and alterations in the expression of the PDE2A gene have been implicated in various diseases and conditions. In the context of malignant melanoma, mutations in PDE2A have been associated with the down-regulation of cyclin A and induction of G2/M arrest, suggesting potential therapeutic targets for treating this type of cancer (Azevedo2013Clinical). In pediatric adrenocortical tumors, a decrease in PDE2A expression has been observed, which may contribute to tumorigenesis by disrupting the cAMP signaling pathway. This imbalance is thought to play a critical role in the development of these tumors, highlighting PDE2A as a potential therapeutic target (Pinto2020Germline).

PDE2A is also involved in the regulation of mitochondrial morphology and apoptotic cell death through the cAMP/PKA signaling pathway. Inhibition of the PDE2A2 isoform can lead to changes in mitochondrial dynamics, providing protection from apoptotic cell death. This has potential therapeutic implications for conditions involving mitochondrial dysfunction, such as neurodegenerative diseases, cancers, and cardiovascular disorders (Monterisi2017PDE2A2). These findings underscore the clinical significance of PDE2A in various pathological conditions and its potential as a target for therapeutic intervention.

## Interactions
Phosphodiesterase 2A (PDE2A) interacts with several proteins, forming complexes that influence various cellular processes. One significant interaction is with the co-chaperone XAP2, identified through yeast two-hybrid screening. This interaction was confirmed by pulldown assays and co-immunoprecipitation experiments, demonstrating that PDE2A and XAP2 bind in intact cells. The GAF-B domain of PDE2A mediates this binding, while the carboxyl-terminal TPR domain of XAP2 is required for the interaction. This complex is involved in regulating the nuclear translocation of the aryl hydrocarbon receptor (AhR), affecting gene expression related to detoxification (de2007Phosphodiesterase).

PDE2A2, an isoform of PDE2A, interacts with components of the MICOS complex, particularly MIC60 and MIC19, which are crucial for mitochondrial structure and function. This interaction is isoform-specific and involves the regulatory GAF-B domain of PDE2A2. It plays a role in mitochondrial dynamics, including the regulation of cAMP levels and PKA-mediated phosphorylation, influencing processes like mitophagy and apoptosis (Lobo2020Phosphodiesterase; Monterisi2017PDE2A2).

These interactions highlight PDE2A's role in multiprotein complexes, linking cAMP-dependent signaling pathways with cellular functions such as detoxification and mitochondrial regulation.


## References


[1. (Pandit2009Mechanism) Jayvardhan Pandit, Michael D. Forman, Kimberly F. Fennell, Keith S. Dillman, and Frank S. Menniti. Mechanism for the allosteric regulation of phosphodiesterase 2a deduced from the x-ray structure of a near full-length construct. Proceedings of the National Academy of Sciences, 106(43):18225–18230, October 2009. URL: http://dx.doi.org/10.1073/pnas.0907635106, doi:10.1073/pnas.0907635106. This article has 133 citations.](https://doi.org/10.1073/pnas.0907635106)

[2. (de2007Phosphodiesterase) Simone Kobe de Oliveira, Meike Hoffmeister, Stepan Gambaryan, Werner Müller-Esterl, Jorge A. Guimaraes, and Albert P. Smolenski. Phosphodiesterase 2a forms a complex with the co-chaperone xap2 and regulates nuclear translocation of the aryl hydrocarbon receptor. Journal of Biological Chemistry, 282(18):13656–13663, May 2007. URL: http://dx.doi.org/10.1074/jbc.m610942200, doi:10.1074/jbc.m610942200. This article has 85 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m610942200)

[3. (Lobo2020Phosphodiesterase) Miguel J. Lobo, Laia Reverte-Salisa, Ying-Chi Chao, Andreas Koschinski, Frank Gesellchen, Gunasekaran Subramaniam, He Jiang, Samuel Pace, Natasha Larcom, Ester Paolocci, Alexander Pfeifer, Sara Zanivan, and Manuela Zaccolo. Phosphodiesterase 2a2 regulates mitochondria clearance through parkin-dependent mitophagy. Communications Biology, October 2020. URL: http://dx.doi.org/10.1038/s42003-020-01311-7, doi:10.1038/s42003-020-01311-7. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-020-01311-7)

[4. (Azevedo2013Clinical) Monalisa F. Azevedo, Fabio R. Faucz, Eirini Bimpaki, Anelia Horvath, Isaac Levy, Rodrigo B. de Alexandre, Faiyaz Ahmad, Vincent Manganiello, and Constantine A. Stratakis. Clinical and molecular genetics of the phosphodiesterases (pdes). Endocrine Reviews, 35(2):195–233, December 2013. URL: http://dx.doi.org/10.1210/er.2013-1053, doi:10.1210/er.2013-1053. This article has 228 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/er.2013-1053)

[5. (Sadhu1999Differential) Krishna Sadhu, Kelly Hensley, Vince A. Florio, and Sharon L. Wolda. Differential expression of the cyclic gmp-stimulated phosphodiesterase pde2a in human venous and capillary endothelial cells. Journal of Histochemistry &amp; Cytochemistry, 47(7):895–905, July 1999. URL: http://dx.doi.org/10.1177/002215549904700707, doi:10.1177/002215549904700707. This article has 60 citations.](https://doi.org/10.1177/002215549904700707)

[6. (Iffland2005Structural) André Iffland, Darcy Kohls, Simon Low, Jing Luan, Yan Zhang, Michael Kothe, Qing Cao, Ajith V. Kamath, Yuan-Hua Ding, and Tom Ellenberger. Structural determinants for inhibitor specificity and selectivity in pde2a using the wheat germ in vitro translation system. Biochemistry, 44(23):8312–8325, May 2005. URL: http://dx.doi.org/10.1021/bi047313h, doi:10.1021/bi047313h. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi047313h)

[7. (Martinez2002The) Sergio E. Martinez, Albert Y. Wu, Natalie A. Glavas, Xiao-Bo Tang, Stewart Turley, Wim G. J. Hol, and Joseph A. Beavo. The two gaf domains in phosphodiesterase 2a have distinct roles in dimerization and in cgmp binding. Proceedings of the National Academy of Sciences, 99(20):13260–13265, September 2002. URL: http://dx.doi.org/10.1073/pnas.192374899, doi:10.1073/pnas.192374899. This article has 216 citations.](https://doi.org/10.1073/pnas.192374899)

[8. (Hamza2009Determination) Adel Hamza and Chang-Guo Zhan. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation. The Journal of Physical Chemistry B, 113(9):2896–2908, February 2009. URL: http://dx.doi.org/10.1021/jp8082612, doi:10.1021/jp8082612. This article has 17 citations.](https://doi.org/10.1021/jp8082612)

[9. (Pinto2020Germline) Emilia Modolo Pinto, Fabio R. Faucz, Luana Z. Paza, Gang Wu, Elizabeth S. Fernandes, Jerome Bertherat, Constantine A. Stratakis, Enzo Lalli, Raul C. Ribeiro, Carlos Rodriguez-Galindo, Bonald C. Figueiredo, and Gerard P. Zambetti. Germline variants in phosphodiesterase genes and genetic predisposition to pediatric adrenocortical tumors. Cancers, 12(2):506, February 2020. URL: http://dx.doi.org/10.3390/cancers12020506, doi:10.3390/cancers12020506. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers12020506)

[10. (Monterisi2017PDE2A2) Stefania Monterisi, Miguel J Lobo, Craig Livie, John C Castle, Michael Weinberger, George Baillie, Nicoletta C Surdo, Nshunge Musheshe, Alessandra Stangherlin, Eyal Gottlieb, Rory Maizels, Mario Bortolozzi, Massimo Micaroni, and Manuela Zaccolo. Pde2a2 regulates mitochondria morphology and apoptotic cell death via local modulation of camp/pka signalling. eLife, May 2017. URL: http://dx.doi.org/10.7554/elife.21374, doi:10.7554/elife.21374. This article has 106 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.21374)